

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

NCT07138755

Status	RECRUITING
Phase	Phase 2
Sponsor	The Third Xiangya Hospital of Central South University
Enrollment	35 participants

Key Eligibility Criteria

Inclusion (8)

- The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study
 - Age range of 18-75 years old upon enrollment, both male and female are eligible
 - Stage III NSCLC confirmed by histology or cytology (according to the International Union Against Cancer and the Joint American Committee on Cancer 8th edition TNM staging of lung cancer)
 - It was clarified that surgical resection is not possible After MDT discussion,
 - The main driver genes have no sensitive mutations (including EGFR, ALK, ROS1, MET, HER2, etc.)
- ... and 3 more (see full listing online)

Exclusion (22)

- There are any small cell carcinoma components present in the histopathology, as well as special types such as salivary gland type and SMARCA4 deficiency
 - Except for NSCLC, the subjects had other malignant tumors within the 5 years prior to enrollment. Subjects with other tumors that have been cured by local treatment, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ, are not excluded
 - Previously received local treatments for tumor lesions such as thoracic radiotherapy and radiofrequency ablation
 - Received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., excluding IL-11 used to treat thrombocytopenia) within 2 weeks before the first administration; Received Chinese herbal medicine or traditional Chinese patent medicines and simple preparations with anti-tumor indications within 1 week before the first administration
 - Suffering from active autoimmune diseases that require systematic treatment within the past two years
- ... and 17 more (see full listing online)

Locations (1 total)

Xiangya 3rd Hospital, Central South University, Changsha, Hunan, China

<https://clinicaltrials.gov/study/NCT07138755>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.